SARS-CoV-2 (COVID-19) ORF8 Antibody
Infectious Disease, COVID-19
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC, E |
---|---|
Primary Accession | P0DTC8 |
Other Accession | P0DTC8 |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | IgG |
Clone Names | ORF8 |
Calculated MW | 13831 Da |
Application Notes | WB: 1 μg/mL; IHC: 0.1 μg/mL Antibody validated: Immunohistochemistry in human samples. SARS-CoV-2 (COVID-19) ORF8 antibody can detect 2 ng of free peptide at 1 μg/mL in ELISA. It can detect SARS-CoV-2 ORF8 recombinant protein by ELISA and WB. All other applications and species not yet tested. |
Gene ID | 43740577 |
---|---|
Other Names | ORF8 protein, ns8, ORF8, Non-structural protein 8 |
Target/Specificity | ORF8 Antibody is predicted to not cross-react with other coronavirus family members. |
Reconstitution & Storage | SARS-CoV-2 (COVID-19) ORF8 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
Precautions | SARS-CoV-2 (COVID-19) ORF8 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | 8 |
---|---|
Function | Plays a role in modulating the host immune response (PubMed:31986261, PubMed:35343786, PubMed:36689483). May act as a secreted virokine by mimicking interleukin-17A (IL17A), and thereby binding to the IL17RA receptor, leading to activation of the IL17 pathway and increased secretion of pro-inflammatory factors (PubMed:35343786, PubMed:36689483). Contributes to the cytokine storm during SARS-CoV-2 infection when secreted by unconventional pathway (PubMed:33723527, PubMed:36689483). May act by down-regulating major histocompability complex class I (MHC-I) at cell surface (PubMed:34021074, PubMed:35157849). May inhibit expression of some members of the IFN-stimulated gene (ISG) family including hosts IGF2BP1/ZBP1, MX1 and MX2, and DHX58 (PubMed:34177923). |
Cellular Location | Secreted. Note=Is secreted during a normal viral infection by unconventional pathway (PubMed:35157849, PubMed:36689483) Its mRNA is expressed in cytoplasm and not spliced during a viral infection, but is spliced when expressed from cDNA in nucleus (PubMed:35157849). Splicing changes localization to host endosome and/or cytoplasm (PubMed:33060197, PubMed:34177923). May also localize in nucleus when fused with GFP (PubMed:34177923) |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). SARS-CoV-2 virus proteins include structural proteins, non-structural proteins and accessory factors. The structure of SARS-CoV-2 consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. SARS-CoV-2 non-structural protein is ORF1ab that consists of 16 proteins (nsp1-nsp16), while accessory factors include ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8, ORF9b, ORF9c and ORF10. ORF8 may play a role in modulating host immune response (Probable). May play a role in blocking host IL17 cytokine by its interaction with host IL17RA (3).
References
Gorbalenya. bioRxiv: 2020.;Hui et al. Int J Infect Dis. 2020;91:264-266.;Chan et al. Lancet. 2020; 395:514-523.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.